6月30日（路透社）—— Pacira Pharmaceuticals 公司宣布，已与齐默巴奥米特控股达成一项协议，将剥离其 Iovera° 业务。根据协议，Pacira Pharmaceuticals 将因此次剥离获得高达1.4亿美元的收入。此外，该公司在2031年12月31日之前，还有资格获得最高可达7000万美元的潜在里程碑付款。Pacira Pharmaceuticals 计划将此次交易获得的前期收益用于偿还其高级有担保循环信贷额度。
6月30日（路透社）—— Pacira Pharmaceuticals 公司宣布，已与齐默巴奥米特控股达成一项协议，将剥离其 Iovera° 业务。根据协议，Pacira Pharmaceuticals 将因此次剥离获得高达1.4亿美元的收入。此外，该公司在2031年12月31日之前，还有资格获得最高可达7000万美元的潜在里程碑付款。Pacira Pharmaceuticals 计划将此次交易获得的前期收益用于偿还其高级有担保循环信贷额度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.